2,5-dichloro-N-(cyclopentylmethyl)pyrimidin-4-amine | 1351762-10-1

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 2,5-dichloro-N-(cyclopentylmethyl)pyrimidin-4-amine
• CAS: 1351762-10-1
• 化学式: C₁₀H₁₃Cl₂N₃
• 分子量: 246.139
• InChiKey: XAOXJXPUPZGPOL-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.9
• 重原子数：
  15
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.6
• 拓扑面积：
  37.8
• 氢给体数：
  1
• 氢受体数：
  3

文献信息

• [EN] 2-(PHENYL OR PYRID-3-YL) AMINOPYRIMIDINE DERIVATIVES AS KINASE LRRK2 MODULATORS FOR THE TREATMENT OF PARKINSON'S DISEASE<br/>[FR] DÉRIVÉS 2-(PHÉNYL OU PYRID-3-YL)AMINOPYRIMIDINES EN TANT QUE MODULATEURS DE LA KINASE LRRK2 POUR LE TRAITEMENT DE LA MALADIE DE PARKINSON
  申请人：HOFFMANN LA ROCHE

  公开号：WO2013079495A1

  公开（公告）日：2013-06-06

  Compounds of the formula (I), or pharmaceutically acceptable salts thereof, wherein m, n. X, R1, R2, R3, R4 and R5 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  化合物的结构式（I），或其药用盐，其中m、n、X、R1、R2、R3、R4和R5的定义如本文所述。还公开了制备这些化合物的方法，并将这些化合物用于治疗与LRRK2受体相关的疾病，如帕金森病。
• AMINOPYRIMIDINE DERIVATIVES AS LRRK2 INHIBITORS
  申请人：Baker-Glenn Charles

  公开号：US20110301141A1

  公开（公告）日：2011-12-08

  Compounds of the formula I: or pharmaceutically acceptable salts thereof, wherein m, n. X, R 1 , R 2 , R 3 , R 5 , R 6 and R 7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  化合物的公式I：或其药用盐，其中m，n，X，R1，R2，R3，R5，R6和R7的定义如本文所述。还公开了制备这些化合物的方法以及将这些化合物用于治疗与LRRK2受体相关的疾病，如帕金森病。
• [EN] INHIBITORS OF ACK1/TNK2 TYROSINE KINASE<br/>[FR] INHIBITEURS DE LA TYROSINE KINASE ACK1/TNK2
  申请人：H LEE MOFFITT CANCER CENTER & RES INST

  公开号：WO2017023899A1

  公开（公告）日：2017-02-09

  Described are cancer therapies and anti-cancer compounds. In particular, disclosed are ihibitors of ACK1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new ACK1 tyrosine kinase inhibitors are also disclosed. In specifc example, compound having Formula I are disclosed.

  本文描述了癌症治疗和抗癌化合物。特别地，本文披露了ACK1酪氨酸激酶抑制剂及其在癌症治疗中的应用。本文还披露了筛选新的ACK1酪氨酸激酶抑制剂的方法。在具体的例子中，披露了具有I式的化合物。
• AMINOPYRIMIDINE DERIVATIVES AS LRRK2 MODULATORS
  申请人：Genentech, Inc.

  公开号：US20130157999A1

  公开（公告）日：2013-06-20

  Specific Compounds of formula I: or pharmaceutically acceptable salts thereof, wherein m, X, R 1 , R 2 , R 3 , R 5 , R 6 and R 7 are as defined herein. Also disclosed are methods of making the compounds and using the compounds for treatment of diseases associated with LRRK2 receptor, such as Parkinson's disease.

  公式I的特定化合物或其药学上可接受的盐，其中m，X，R1，R2，R3，R5，R6和R7的定义如本文所述。还揭示了制备这些化合物的方法，并使用这些化合物治疗与LRRK2受体相关的疾病，如帕金森病。
• Inhibitors of ACK1/TNK2 tyrosine kinase
  申请人：H. LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE, INC.

  公开号：US10336734B2

  公开（公告）日：2019-07-02

  Described are cancer therapies and anti-cancer compounds. In particular, disclosed are inhibitors of ACK1 tyrosine kinase and their use in the treatment of cancer. Methods of screening for new ACK1 tyrosine kinase inhibitors are also disclosed. In specific example, compound having Formula I are disclosed.

  所述的是癌症疗法和抗癌化合物。特别是，公开了 ACK1 酪氨酸激酶的抑制剂及其在治疗癌症中的用途。还公开了筛选新的 ACK1 酪氨酸激酶抑制剂的方法。在具体实例中，公开了具有式I的化合物。